Dompe Release: The First Patient Has Been Enrolled in the First International Clinical Trial of rhNGF for the Treatment of Neurotrophic Keratitis
Published: Feb 14, 2013
MILAN--(BUSINESS WIRE)--The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK). The drug was developed on the basis of the experimental studies conducted by the late Professor Rita Levi Montalcini, who was awarded the Nobel Prize for her discovery of this signalling protein involved in the development of the nervous system. The first patient with this rare, sight-threatening degenerative disease of the cornea, which afflicts one in 10,000 people throughout the world, was recruited at San Raffaele Hospital in Milan. The clinical trial is sponsored by Dompé, one of Italy’s leading biopharmaceutical companies, dedicated to finding innovative therapeutic solutions for diseases that have a high social impact in the areas of diabetes, ophthalmology and oncology.